secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001628280-24-007972
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology: $75M cash, 50% ORR in ONSEMBLE bev naïve, first patient dosed in CRDF-004 trial
--------------------------------------------------------------------------------

- Cash and equivalents of $75M as of Dec 31, 2023; projected runway into Q3 2025.
- ONSEMBLE: 50% ORR (2/4) in bev naïve patients on onvansertib+SoC vs 0% in control; no responses in bev exposed.
- First patient dosed in Phase 2 first-line CRDF-004 trial for RAS-mutated mCRC; topline data expected mid-2024.
- Pfizer Ignite handling clinical execution; FDA accepted ORR as endpoint for potential accelerated approval.
- FY2023 operating expenses $45.9M, net cash used $30.9M; decrease from $33.8M in FY2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828024007972/0001628280-24-007972-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828024007972/crdf-20240229.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-007972

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer